Hitachi Ventures

Reinforcing recycling, rerouting refuse, and reducing wasteflows

Waste Recovery & Management Tech

Cyclic Materials is an Ontario-based advanced metals recycling company focused on recovering rare earth elements (REE) used in high-performance magnets from end-of-life products. It re-circulates REEs back into the supply chains of automobiles, renewable wind energy, electronics, and more. Additionally, the company’s process recycles copper, aluminum, steel, cobalt, and nickel—metals that are also required for electrification and decarbonization. Cyclic Materials' closed-loop process reportedly uses less than 2% of the water and requires only 40% of the CO2 emissions of newly mined material.&nbsp;In February 2024, Cyclic Materials expanded to process <a href="https://sp-edge.com/updates/27086">two new streams</a>, wind turbine generators and MRI machines to create a circular supply chain that feeds these critical metals back into the North American and European markets.Cyclic's first facility, operational since September 2023, processes approximately 2,200 pounds of devices per hour, or nearly 18 million pounds per year, using its Mag-Xtract magnet removal process. Additionally, its hydrometallurgical process, which underwent trial runs in 2022, has an initial capacity of 22,000 lbs per year. As of March 2024, the company was developing its first commercial demonstration plant for this technology in Kingston with a target launch date in Q2 2024. Plans are also underway to expand with multiple facilities in the US and Canada.Key customers and partnershipsIn 2022, Cyclic Materials partnered with Polestar for the development of REEs of recycled magnets for use in Polestar cars, as well as explore ways to efficiently recycle existing magnets. ‍In February 2023, the company partnered with<a href="https://www.solvay.com/en/"> </a>Solvay for the production and supply of recycled mixed rare earth oxides (rMREO). The company also partnered with Arnold Magnetic Technologies, a leading magnet manufacturer, in April 2023, to establish a rare earth recycling program that would recycle all elements from Arnold's supply feed. In March 2024, the company partnered with <a href="https://sp-edge.com/updates/27689">Vacuumschmelze</a>, a developer of magnetic materials and solutions, to recycle by-products containing critical materials used in high-performance permanent magnets.Funding and financialsIn April 2023, Cyclic Materials raised USD 27 million in an <a href="https://sp-edge.com/updates/18019">oversubscribed Series A financing</a> round led by Energy Impact Partners (EIP) and BMW i Ventures (BiV) to scale up its technologies for future growth in North America, Europe, and Asia, as well as meet the rising demand for REEs. The company was also among the 17 companies selected to receive USD 3.6 million in funding in February 2023 from the Sustainable Development Technology Council (SDTC) of Canada to support the scaling of their proprietary technology.

Based in Australia, Samsara Eco uses an enzyme-based biocatalyst technology to recycle plastic by breaking it down into molecular building blocks to produce new plastic products, which can be repeated infinitely.&nbsp;As of March 2024, the company operates a <a href="https://sp-edge.com/updates/21494">research laboratory</a> in Queanbeyan, regional New South Wales (NSW), which will scale up Samsara’s patented technology&nbsp; and is expected to be operational by the end of 2024, recycling 20,000 tons of plastic. The company aims to recycle 1.5 million tons of plastic per annum by 2030.Key customers and partnershipsIn February 2024, Samsara Eco partnered with athletic apparel brand <a href="https://sp-edge.com/updates/26944">Lululemon</a> to unveil a version of Lululemon's Swiftly Tech long-sleeve top made from recycled nylon 6,6.Funding and financialsIn <a href="https://sp-edge.com/updates/14206">November 2022</a>, the company raised AUD 54 million (~USD 34.7 million) in a Series A funding round, bringing its total funding up to USD 40.5 million to support the company in building its first commercial 20,000-tonne facility in Melbourne.In October 2023, Samsara received AUD 568,491 (~USD 372,000) from the Federal Government’s Advanced Manufacturing Growth Centre’s (AMGC) Commercialisation Fund.

WASE is a London-based provider of on-site, modular waste-to-energy solutions using its proprietary Electro-Methanogenic Reactor (EMR) technology to convert organic waste and wastewater into valuable resources such as biogas, clean water and digestate, a byproduct for soil nutrition. The clean water produced by EMR technology can be used for irrigation, reducing the need for potable water in agriculture. Its biogas can be used to generate electricity and heat or fuel vehicles, reducing the need for fossil fuels and helping to reduce greenhouse gas emissions. The company claims that its solutions reduce chemical oxygen demand (COD; the amount of oxygen required for oxidation in water) by more than 95% while generating biogas. The company also claims its onsite organic waste treatment solution is 68% smaller in size, 10x faster, and generates 20% more energy than traditional alternatives.&nbsp;As of July 2023, WASE operates three biocenter systems: 1) IndustriWASE for waste-to-energy solutions in the food and beverage sector; 2) AgriWASE for energy and resource recovery in agriculture; and 3) SaniWASE for the safe treatment of municipal waste in underserved communities. In March 2022, WASE announced its plans to install over 1,000 IndustriWASE systems in the next five years, generating over 500 gigawatt hours of renewable energy and saving over 140,000 tons of carbon.Key customers and partnershipsWASE partnered with Hitachi in August 2022 to explore business opportunities in Japan and Southeast Asia for its IndustriWASE electro-methanogenic reactors. The two companies began developing business prospects with a particular focus on the international F&amp;B industry, including economic and technical feasibility analysis, conducting pilot-scale testing, and ultimately developing a business strategy for commercialization in Japan. As of June 2023, the two companies have completed a pilot project at Hepworth Brewery, a brewery in the UK, and are evaluating additional aspects of their technology for further refinement and development.Funding and financialsIn March 2022, the company raised GBP 700,000 (~USD 911,781) in seed funding from Elbow Beach Capital, Science Angel Syndicate, and the European Union's Climate-KIC investment support program to install a commercial industrial biocenter system at Hepworth Brewery, advance WASE's sales pipeline, increase R&amp;D spending, and support hiring. In February 2023, the company received an undisclosed grant from the Department for Energy Security &amp; Net Zero's Energy Entrepreneurs Fund to further develop its EMR technology and test its agriWASE system.

Ascend Elements (previously known as Battery Resourcers) takes old cathode material and processes them to create new cathode materials, to meet the needs of cell manufacturing. Ascend Elements also recycles spent lithium-ion batteries into value-added battery-ready cathode active materials.&nbsp;The company reports that its technology which involves the hydro process recycling and direct recycling technologies allow in 97% metal recovery and production of Nickel Manganese Cobalt (NMC)-based cathode active materials at a 35% reduction in cost, 32% reduction in emissions, and&nbsp;13% reduction in energy consumption, compared to the production of virgin cathodes. The company also claims that it can recycle and produce cathode materials at 50% of the cost of newly mined metals. As of March 2024, the company manufactures its products in North America and Europe, and it targets battery producers and vehicle equipment manufacturers, having partnered with players such as <a href="https://sp-edge.com/updates/16689">Honda</a>, Jaguar Land Rover, <a href="https://sp-edge.com/updates/9004">SK Battery America (SKBA)</a>, and <a href="https://sp-edge.com/updates/13777">EcoPro Group</a>.&nbsp;In March 2023, Ascend Elements <a href="https://sp-edge.com/updates/17477">commenced</a> operations at its <a href="https://sp-edge.com/updates/7596?industryIds=54">154,000 square-foot lithium-ion battery recycling facility</a> in Covington, Georgia. The facility can process 30,000 metric tons of end-of-life batteries and battery scrap per year(~70,000 vehicle batteries per year), and has reportedly become North America’s largest lithium-ion battery recycling facility. As of March 2024, the company was building a USD 1 billion lithium-ion battery recycling facility in Kentucky, expected to come online by 2025 and produce battery materials for up to 750,000 EVs per year. It also set a long-term target to build new facilities across North America, Europe, and Asia to process up to 150,000 metric tons of lithium-ion batteries annually.Key customers and partnershipsThe company partnered with Koura, a global leader in the development, manufacture, and supply of fluoroproducts, in <a href="https://sp-edge.com/updates/17070">March 2023</a>, to supply Koura with up to 5,000 metric tonnes of recycled and recovered lithium carbonate per year. In <a href="https://sp-edge.com/updates/22816">October 2023</a>, they advanced the partnership to jointly commercialize the patented graphite recycling technology in the US. In August 2023, the company partnered with <a href="https://sp-edge.com/updates/21139">Call2Recycle</a> to safely manage end-of-life EV batteries using Call2Recycle's GreenTraxEV platform. In September 2023, the company partnered with <a href="https://sp-edge.com/updates/21794">Freudenberg e-Power Systems</a> to develop a sustainable cathode-active material (CAM). During the same period, the company formed a joint venture with <a href="https://sp-edge.com/updates/22168">SK Ecoplant</a> to build a battery recycling pretreatment plant in Kentucky which will be able to produce 12,000 tons of black mass from January 2025.&nbsp;Funding and financialsIn <a href="https://sp-edge.com/updates/26811">February 2024</a>, Ascend Elements raised USD 162 million in a Series D round to support the construction of Apex 1. Previously, in <a href="https://sp-edge.com/updates/21610">September 2023</a>, when the company raised USD 542 million in a Series D funding round led by Decarbonization Partners, Temasek, and Qatar Investment Authority. The funds were to be used for construction of Apex 1.

Leveraging personal data for custom-fit diagnosis and treatment

Precision Medicine

Scipher Medicine, a precision immunology company, focuses on matching each patient with their most effective therapy, believing that treatment options should be based on clear scientific data. Utilizing Spectra, a proprietary network medicine platform, Scipher develops tests that reveal a person’s unique molecular disease signature and match it to the most effective therapy, claiming to ensureoptimal treatment from the start. The molecular data generated by their tests also supports the discovery and development of novel, more effective therapeutics. Its first commercially available product, PrismRA, is a blood test developed to identify patients that are unlikely to respond to TNF inhibitor therapies, a commonly used treatment for rheumatoid arthritis (RA), and provide alternative options. The company claims this first-of-its-kind molecular test analyzes 23 biological features to generate insights that can help healthcare providers with RA treatment decisions. The B2B2C company partners with payers, health care providers, and pharmaceutical companies such as UnitedHealth Group, Johnson &amp; Johnson, Ambry Genetics, and Optum.Scipher Medicine’s Spectra AI Platform offers an approach to identifying the biological mechanisms that influence drug response. This insight into disease biology enables Scipher to discover new therapeutic targets, find new uses for existing drugs, and improve patient stratification.

<div>
 
 Proscia&rsquo;s AI-powered platform, Concentriq Dx, facilitates precision medicine by providing applications that support pathologists with research and diagnosis of cancer. It also offers clinical insights to diagnostic laboratories and pharmaceutical companies. Precision medicine drug developers use the platform for biomarker analysis, patient stratification, and the creation of large repositories of data that aid the drug development process.
 
 
 The Philadelphia-based firm provides a broad portfolio of AI applications including DermaAI, a melanoma detection solution, and Automated Quality Control (QC) for performing QC on images. Its Concentriq Dx platform was certified under In Vitro Diagnostic Regulation (IVDR) for use in primary diagnosis, enabling its use in the European diagnostic pathology market. In addition to the US, the firm has set up operations in Ireland and Spain.&nbsp;
 
 
 Key customers and partnerships&nbsp;
 
 
 As of June 2023, the firm&rsquo;s user base included 10 large pharmaceutical companies, reference laboratories, and health systems. Proscia has also partnered with the Joint Pathology Center to digitize the latter&rsquo;s human tissue repository of more than 55 million slides. In addition, the company has an original equipment manufacturing agreement with Siemens Healthineers.&nbsp;
 
 
 <a href="https://sp-edge.com/updates/16966">
 In March 2023 
 </a>
 , the company signed a multi-year distribution agreement with life science company Agilent Technologies, to provide a digital system for diagnosing pathology. The company also announced that Concentriq for Research has been chosen by contract research organization (CRO) 
 <a href="https://sp-edge.com/updates/17239">
 Altasciences 
 </a>
 to help its sponsors provide life-saving treatments to patients more quickly and 
 <a href="https://sp-edge.com/updates/17954">
 Virscio 
 </a>
 to provide faster and more informed drug safety insights.&nbsp;
 
 
 <a href="https://sp-edge.com/updates/19551">
 In June 2023
 </a>
 , the company partnered with Mindpeak, an AI-powered software developer, to provide an improved diagnosis for cancer patients through integrated AI-powered workflows in pathology.
 
 
 Funding and financials
 
 
 The firm&rsquo;s latest funding round took place in June 2022, where it raised USD 37 million in a Series C funding round. The funds were allocated toward further expediting the adoption of its pathology platform, launching new solutions, and introducing other third-party applications. The firm also planned to scale its operations by expanding its distribution partnerships as well as expanding its sales, marketing, and support teams.
 
</div>

<div>
 
 SOPHiA GENETICS is a bioinformatics company providing genomic and radiomic analysis services to hospitals, laboratories, and biopharma institutions. Its cloud-based SaaS analytics platform, SOPHiA DDM, facilitates insights from complex multimodal datasets across various disease areas, such as oncology, rare diseases, infectious diseases, cardiology, neurology, and metabolism. Using ML and patented algorithms, it calls, annotates, and pre-classifies variants from raw next-gen sequencing data. The platform evolves with ongoing data analysis, improving over time.
 
 
 Customers maintain control over their samples and data, using the SOPHiA DDM platform to analyze data and exchange insights, contributing to a shared knowledge pool. As of October 2023, the platform had supported the analysis of over 1.2 million genomic profiles. Additionally, the company provides genomics mutation interpretation software, Alamut, offering advanced analytics for more comprehensive genomic data interpretation. SOPHiA GENETICS follows a B2B model, serving the clinical and biopharma markets.
 
 
 Key partnerships and customers
 
 
 As of October 2023, SOPHiA GENETICS had partnerships with 750+ institutions across 72 countries.
 
 
 Funding and financials
 
 
 SOPHiA GENETICS went public on the Nasdaq in 2021, floating at USD 1.1 billion under the ticker symbol &quot;SOPH.&quot; For 2022, the company reported a net loss of USD 87.4 million (up 19% YoY), while revenue amounted to USD 47.6 million (up 18% YoY).
 
</div>

Using data and automation to achieve 24/7 production.

Smart Factory

ThinkIQ offers a platform for manufacturers to collect, visualize, integrate, and derive insights from data to identify abnormalities in equipment and processes, with a view to continuous operational improvements. The company targets food and beverage, chemical, and pharmaceutical manufacturers.The company utilizes AI and machine learning to reveal material movements, identifying new insights and improvement opportunities in manufacturing processes. ThinkIQ's technology includes a historian that maintains supply chain and manufacturing data for analytics, a semantic model that contextualizes sensor data, and a material ledger for supply chain data analytics.&nbsp;ThinkIQ offers five main products to match different stages of automation in a factory: Vision, Visualize, Insight, Transform, and Autonomy. 1) ThinkIQ Vision targets manufacturers that are new to automation by setting up data collection systems using cameras and machine vision to generate data. 2) ThinkIQ Visualize is for manufacturers that already have a way of gathering data—Visualize helps to integrate existing data sources from different hardware (like cameras and sensors) and software (like ERPs and CRMs), allowing customers to see all data in one screen. 3) ThinkIQ Insight offers advanced visualization, cause-and-effect analysis, and cross-plant KPIs. It also provides alerts and notifications on issues that require immediate attention to avoid the risk of recalls. 4) ThinkIQ Transform links KPIs to industry standards and contextualizes the stream of data over time to generate insights. 5) ThinkIQ Autonomy is for the final stage of automation that integrates all manufacturing data with supply chain data as well as customers for better traceability.&nbsp;In May 2023, ThinkIQ launched its <a href="https://sp-edge.com/updates/18824">Continuous Intelligence Platform</a> to all existing ThinkIQ customers and CESMII (the Smart Manufacturing Institute) Smart Manufacturing Innovation Platform (SMIP) users. This was two months after the company received a <a href="https://sp-edge.com/updates/17407?industryIds=6">patent</a> for its technology to trace and analyze material flow in manufacturing processes. Meanwhile, <a href="https://sp-edge.com/updates/21272">In August 2023,</a> ThinkIQ was granted a US patent for its capability to align data for ongoing manufacturing material flow. This technology aids plant engineers, operators, and data scientists in identifying correlations, associations, and underlying factors within the manufacturing process.Key customers and partnershipsIn September 2021, ThinkIQ launched an Alliance Partner Program to help customers maximize their returns on investment in technology. Some of ThinkIQ’s notable partners are AWS, Microsoft, CESMII, Accenture, UST, JMP, and Atollogy.&nbsp;In January 2024, ThinkIQ partnered with Mitsubishi Corporation to accelerate the growth of its digital manufacturing platform in Japan, focusing on smart manufacturing solutions for industrial supply chains.

Artificial intelligence is identifying and testing new therapies faster than ever.

AI Drug Discovery

<div>
 
 Proscia&rsquo;s AI-powered platform, Concentriq Dx, facilitates precision medicine by providing applications that support pathologists with the research and diagnosis of cancer. It also offers clinical insights to diagnostic laboratories and pharmaceutical companies. Precision medicine drug developers use the platform for biomarker analysis, patient stratification, and the creation of large repositories of data that aid the drug development process.
 
 
 The company also provides a broad portfolio of other AI applications including DermaAI, a melanoma detection solution, and Automated QC, a tool to optimize the quality control process on CT images.&nbsp;
 
 
 In addition to the US, the firm runs operations in Ireland and Spain.&nbsp;
 
 
 Key customers and partnerships&nbsp;
 
 
 As of March 2024, Proscia&rsquo;s Concentriq platform was used by more than 10,000 pathologists and scientists globally, including reference labs, academic medical centers, and 14 of the top 20 pharmaceutical companies. Recently, the company was chosen by PathGroup (
 <a href="https://proscia.com/press-releases/pathgroup-chooses-proscia-to-deliver-next-generation-of-cancer-diagnosis-for-millions-of-patients/">
 March 2023
 </a>
 ), Altasciences (
 <a href="https://sp-edge.com/updates/17239">
 March 2023
 </a>
 ) and Virscio (
 <a href="https://sp-edge.com/updates/17954">
 April 2023
 </a>
 ) to advance their digital pathology capabilities.&nbsp;
 
 
 The company has established partnerships with key companies&nbsp; including Joint Pathology Center to digitize the human tissue repository of more than 55 million slides (
 <a href="https://proscia.com/press-releases/joint-pathology-center-selects-proscias-concentriq-for-modernization-of-worlds-largest-human-tissue-repository/">
 October 2020
 </a>
 ), and Siemens Healthineers to enter an original equipment manufacturing agreement (
 <a href="https://proscia.com/press-releases/proscia-and-siemens-healthineers-ink-agreement-to-expand-global-reach-of-digital-pathology/">
 March 2022
 </a>
 ). &nbsp;Further, in 
 <a href="https://sp-edge.com/updates/19551">
 June 2023,
 </a>
 the company partnered with Mindpeak to provide an improved diagnosis for cancer patients through integrated AI-powered workflows in pathology. Other ecosystem partners include Microsoft, AWS, Ibex Medical Analytics, NVIDIA, and Dell Technologies.
 
 
 Funding and financials
 
 
 In 
 <a href="https://sp-edge.com/updates/27544">
 March 2024
 </a>
 , the company raised USD 46 million in Series C funding round led by Highline Capital Management and Triangle Peak Partners. The funds were intended to scale commercial growth and further develop AI-enabled applications. 
 
</div>

Quantum information processing is slowly becoming a reality, ushering in a new technological era.

Quantum Computing

Strangeworks, based in Austin, Texas, is a company focused on democratizing quantum computing. Founded by William Hurley (aka whurley), the company aims to make quantum technology accessible to those who can leverage its potential for significant advancements.Key customers and partnershipsIn February 2022, <a href="https://sp-edge.com/updates/8704">Quantum Algorithms Institute </a>(QAI) joined the Strangeworks Quantum Syndicate (SQS), the quantum computing hub of Strangeworks, to jointly develop the quantum ecosystem in British Columbia and Canada. In January 2022, the company partnered with <a href="https://sp-edge.com/updates/7594">Quantinuum </a>to integrate the latter’s quantum-enhanced cryptographic key generation platform Quantum Origin into the Strangeworks ecosystem.Funding and financialsIn March 2023, Strangeworks raised USD 24 million in a <a href="https://sp-edge.com/updates/17226">Series A </a>funding round led by Hitachi Ventures, along with participation from other corporate venture capital funds, including IBM and Raytheon. The funds were earmarked to expand the company’s team and for product development initiatives in areas such as quantum-inspired, high-performance computing and AI.

Moving industry forward with next-gen advancements in energy storage and transmission

Alternative Energy

Thea Energy is a spin-off of Princeton University’s plasma physics lab and develops stellarator technology-based fusion power plants.The company’s Eos system, a neutron source stellarator, is claimed to be the only first-generation fusion system power plant prototype. Eos uses an array of computer-controlled high-temperature superconductor (HTS) planar coils, allowing for dynamic field control and simplified maintenance and operations.Thea Energy aims to scale up Eos and launch the Helios Power Plant by 2030 to begin on-the-grid operations.Key customers and partnershipsIn <a href="https://www.globenewswire.com/en/news-release/2023/07/27/2712179/0/en/Thea-Energy-Selected-for-U-S-Department-of-Energy-Public-Private-Partnership-Award-Through-the-Innovation-Network-for-Fusion-Energy-Program.html">July 2023</a>, Thea Energy partnered with the University of California San Diego to develop a boron-based renewable first wall capable of sufficient heat removal and tritium recovery from stellarator fusion devices.Funding and financialsIn <a href="https://sp-edge.com/updates/26493">February 2024</a>, Thea Energy raised USD 20 million in a Series A funding round led by Prelude Ventures. The company intended to use funds to construct and operate the company's superconducting planar coil magnet array systems. Prior to this, in <a href="https://sp-edge.com/updates/19658">May 2023</a>, Thea Energy was selected as an awardee of the USD 46 million milestone-based fusion development program. Split among seven companies, this funding covers the first 18 months of a project with future funding contingent on congressional approval and achievement of milestones.

New technology allows individuals and organizations to become carbon intelligent

Carbon Management Software

UK-based BeZero Carbon provides carbon rating and risk analytics. The company assesses the quality of carbon offsets on the voluntary carbon market. The company uses geospatial analytics to provide a toolkit for evaluating carbon projects around the world.BeZero Carbon Rating provides users with a risk-based assessment of the likelihood of a given carbon credit avoiding or removing a ton of CO2. The BeZero Carbon Rating uses a seven-point scale across three categories—A, AA, AAA. In <a href="https://sp-edge.com/updates/21669">September 2023 </a>, the company introduced a new methodology for discounting carbon credits in the voluntary carbon market (VCM). It is formulated to assist customers in understanding how many credits they should purchase to make a tonne-based claim. On the heels of this development, the company launched the <a href="https://sp-edge.com/updates/22013">industry’s first </a>engineered carbon removal credit rating as an “A” rating for a biochar project. In <a href="https://sp-edge.com/updates/32692">August 2024</a>, BeZero Carbon awarded the first "AAA" rating to Climework's Orca project. In November 2023, the company introduced a <a href="https://sp-edge.com/updates/23657">risk assessment tool</a> to analyze a carbon project's lifecycle.BeZero offers two core services—a web platform and an API. The web platform presents project performance and quality ratings using interactive map-based tools to enable real-time and granular data interrogation. The API serves this data for presentation and analysis on other platforms. Key customers and partnershipsBeZero Carbon rating API partners include <a href="https://sp-edge.com/companies/897238">Cloverly </a>, <a href="https://sp-edge.com/companies/1288131">Patch </a>, <a href="https://sp-edge.com/companies/628832">Xpansiv </a>, Allied Offsets, Emsurge, Senken, and Viridios. In February 2023, the company joined <a href="https://sp-edge.com/updates/16333">Salesforce’s Net Zero Marketplace </a>to list its carbon credit ratings. In October 2023, the company partnered with <a href="https://sp-edge.com/updates/22516">Oka, The Carbon Insurance Company </a>, to integrate its carbon credit ratings into the latter's underwriting platform. In November 2023, BeZero Carbon partnered with <a href="https://sp-edge.com/updates/24206">Planet </a>to scale the former's geospatial analysis and research methodologies with Planet's satellite information. In <a href="https://sp-edge.com/updates/32789">August 2024</a>, the company partnered with Emirates NBD, a banking group in the MENAT region, to provide carbon rating in UAE.&nbsp;Some of the company’s clients include Watershed, Anglo American, Equinor, and Glencore. As of December 2023, BeZero Carbon had rated 360+ offsetting projects.

Sustainably solving the food shortages of the future

Smart Farming

Israeli startup Taranis, focuses on providing a complete digital agronomy solution to farmers using aerial imagery technology across the US, Argentina, Brazil, Russia, Ukraine, and Australia. The company now monitors more than 20 million acres globally, 50% of which is located within the US.&nbsp;The startup captures aerial images using UAVs, which can be analyzed and compared using its own platform, and allows farmers to make precise decisions about planting. The company also operates an area called the “AgroBrain”, which allows precise identification of crop issues. The company claims to account for 70% of the global crop market and equips farmers with the tools to address issues in real time. Similar to peers like Ceres Imaging, Taranis has partnered with incumbent players like John Deere, Syngenta, BASF, and Climate Field View to expand its product reach. As such, Taranis is regarded as a promising startup in global precision agriculture.&nbsp;In 2018, the company expanded its footprint in the US when it acquired Mavrx, a US startup providing aerial imagery solutions to local farmers. Mavrx ran into financial difficulties and consolidation of the two companies yielded attractive opportunities. The consolidation allowed Taranis to integrate Mavrx’s product (full field imagery product with highest resolution on the market) into its platform, thereby fulfilling Taranis’ aim of providing a complete solution. The acquisition strengthened Taranis' offering rather than differentiating it. Taranis believes that further consolidation is likely with imagery and AI solutions.&nbsp;In July 2020, amidst the Covid-19 pandemic, the company raised USD 30 million in Series C funding. Key Investors included Hitachi, Mitsubishi, Micron Ventures, and Vertex Ventures Israel. The company expects to use the funds to create more relevant scouting products for growers through its platform and to also look towards expanding into Asia.&nbsp;Previously in January 2023, Taranis introduced <a href="https://www.prnewswire.com/news-releases/taranis-introduces-acreforward-setting-a-new-standard-for-crop-intelligence-301734306.html">AcreForward</a> which provides unprecedented leaf-level insights into growers' crops at higher frequency throughout the season and captures opportunities in every acre to help ag retailers drive more value from every acre. In <a href="https://www.prnewswire.com/news-releases/taranis-launches-ag-assistant-to-transform-farm-decision-making-302198624.html">July 2024</a>, The company has introduced Ag assistant, powered by a generative AI model that integrates data sources from various modalities – including images, text and audio – and with a profound understanding of agronomy.

Data Infrastructure & Analytics

WEKA is the only data management provider that delivers a software-based solution that supports next-generation workloads with uncompromising speed, scale, simplicity, sustainability, and seamless data portability. The WEKA Data Platform is purpose-built for the cloud and AI era. Its advanced cloud-native architecture is optimized to solve complex data challenges, delivering 10-100x performance improvements, whether running on-premises, in the cloud, at the edge, or in hybrid and multi-cloud environments. WEKA is fueling research and discovery breakthroughs and accelerating business outcomes for leading global enterprises – including eight of the Fortune 50. The company operates in over 20 countries and is backed by dozens of world-class investors.

Incorporating technology to improve efficiency and success rate of clinical trials

Clinical Trial Technology

Huma is a UK- and US-based clinical trial tech startup that provides a digital platform to manage clinical trials, including decentralized clinical trials. The platform can be used throughout the clinical trial process, including patient recruitment, screening, electronic consent, clinical outcome assessments, patient-reported outcomes, and telemedicine. The platform is built up to industry standards in data privacy and security, including ISO 27001, 21 C.F.R. Part 11, and TxP.In June 2023, the company <a href="https://sp-edge.com/updates/19352">received FDA 510(k) Class II FDA clearance </a>for its configurable disease-agnostic platform, including its cardiovascular risk score algorithm. The company received this FDA clearance in partnership with Health Canada and it allows Huma's platform to be used to monitor patients of all ages with any condition, including pediatrics and pregnancy. The Class II clearance also enables the platform to host algorithms that provide automated AI-driven data analytics for diagnosis, screening, clinical decision-making, predictions on health outcomes, and recommendations on dosage.In July 2024, the company was <a href="https://sp-edge.com/updates/31552">estimated to be valued at nearly USD 1 billion</a> when it secured a Series D investment of USD 80 million. Key customers and partnershipsSome of the key partners working with Huma include AstraZeneca, Johnson &amp; Johnson, Bayer, Stanford University, and the University of Cambridge. As of July 2024, the platform supported 3,000+ hospitals and clinics, screened over 35 million individuals, and had 1.8 million active users across 70 countries. Huma was awarded the 2021 Prix Galien Award, which is widely considered the “Nobel Prize” for pharmaceuticals and life sciences.The company announced a partnership with Xyla Elective Care in June 2022, to provide support to the UK’s National Health Service in delivering and managing virtual wards.

Novel therapies to reboot cells and organs

Cell & Gene Therapy

ArsenalBio provides oncology therapeutics based on genetically programmed T-cells that attack solid tumors. The company uses multiomics, machine learning, gene editing, and synthetic biology to produce cell-based oncology therapeutics. The company has developed an “engine” that is able to generate multifunctional T cell therapeutics based on its internally curated library of integrated circuits.As of May 2024, the company had five drug candidates in development, two of which were collaboration programs. Its wholly owned programs include AB-1015 (for the treatment of ovarian cancer), AB-2100 (for the treatment of Kidney cancer), AB-3000 (for the treatment of prostate cancer). AB-1015 and AB-2100 were both in early clinical testing, while AB-3000 was anticipated to receive IND approval between Q4 2025 and Q1 2026. Its collaborative candidates include AB-4000 and AB-5000, both being developed for solid tumor indications. Key customers and partnerships In September 2022, the company partnered with Genentech, a member of the Roche Group, to collaborate on identifying successful T Cell therapies in the field of oncology. Through the partnership, both companies would use AresenalBio’s technology for screening and engineering T Cells to identify critical success circuits in T cell-based therapies. Genentech agreed to pay the company USD 70 million in upfront payments along with milestone payments for research, development, and commercialization. ArsenalBio then partnered with Thermo Fisher (TMO) in March 2023 to collaborate on refining the manufacturing processes of cancer treatments. Through the partnership, it would combine knowledge with the aim of assisting ArsenalBio with clinical research and process development capabilities. The companies also agreed to explore future therapeutic innovations.

AI, robotics, and IoT to streamline the flow of goods and information

Logistics Tech

inVia Robotics offers warehouse automation solutions for ecommerce retailers. The company’s solutions include1) “ inVia Picker Robots ,” autonomous mobile robots (AMRs) powered by AI2) “inVia PickerWall,” a dynamic pick-and-put wall system3) “inVia PickMate,” a hardware-agnostic software with a color-based interface that uses a pick-to-color warehouse order-picking technology to make the process of identifying stock-keeping units (SKUs) in the right locations easier4) “ inVia Logic ,” an AI-powered Warehouse Execution System (WES) software and a full-service robotics operations center5) <a href="https://sp-edge.com/updates/30017">“Twin IQ,”</a> an intelligent warehouse simulation platform to streamline operations. The company operates on a subscription-based robotics-as-a-service (RaaS) business model. Key customers and partnershipsinVia Robotics’ customers include Scholastic Canada, ShipHero, Mohawk Industries, Gnarlywood, Stord, Cargo Cove, Fulfyld, Kantsu, SICK, and CarParts.com. The company’s products partnerships include Cubiscan to develop warehouse automating systems (November 2022) and Rufus Labs, a provider of intelligent wearable warehouse technology and workforce analytics software, to offer advanced products with combined technologies (June 2021).

Automation in clinical diagnostics to improve speed and accuracy in patient diagnosis and treatment.

Clinical Decision Support Systems

Proscia is a software company that develops digital and computational pathology solutions. Its flagship product, Concentriq, is an enterprise pathology platform that serves as a hub for digital pathology data and AI applications. Concentriq bridges the gap between anatomic pathology laboratories and life sciences organizations, enabling real-world pathology data to fuel innovation that enhances patient care.
The platform delivers an open environment to run a range of AI applications, including Proscia's proprietary algorithms and those developed by partners or customers. One such AI solution is DermAI, a dermatopathology module launched in June 2019 to assist laboratories in tasks like case prioritization, automated quality assurance, and enhanced technical component reporting.
In February 2024, Proscia received 510(k) clearance from the FDA for its Concentriq AP-Dx solution for primary diagnosis in clinical settings. This comprehensive diagnostic software streamlines collaboration and helps drive confidence and efficiency gains. As of December 2023, over 10,000 pathologists and scientists, including those at leading diagnostic laboratories and 14 of the top 20 pharmaceutical companies, used Proscia's solutions.
Furthermore, in December 2023, CellNetix Pathology & Laboratories announced a collaboration with Proscia to digitize a portion of its 1 million glass slides per year and adopt AI-powered digital pathology workflows.

Automation to improve business efficiency

Workflow Automation Platforms

Ema offers Universal AI Employee, an AI-powered tool for workplaces, capable of executing tasks across various fields to improve technological integration and productivity. Designed to mimic the functions of a human worker, Ema is capable of participating in dialogues, understanding contexts, assimilating ongoing human feedback, reasoning, making decisions, and cooperating with human colleagues on challenging assignments. Ema can automatically resolve a large percentage of tickets, assists agents with relevant information while building and updating the knowledge base for training. It utilizes a proprietary Generative Workflow Engine to automate complex workflows and pulls data from various internal and external sources including enterprise apps, enterprise content, and web data for real-time market updates on regulations, emerging trends, and market competition.Ema utilizes EmaFusion, a collection of 100+ models (as of August 2024), including GPT-4 by OpenAI, Gemini by Google, Mistral by Mistral AI, Llama-2 by Meta, and its own models. Some of its use cases are sales agent assistance, customer inquiry management, lead management, generating responses and summaries for new request for proposals (RFPs), and checking whether contracts are in compliance with changing regulations.Key customers and partnershipsSome of Ema’s customers as of May 2024 included Moneyview and TrueLayer.As of August 2024, the platform also integrated with over 200 file storage, accounting, ticketing, CRM, ATS, marketing, and HR apps.

A new generation for mobile connectivity with 5G and beyond

Next-gen Mobile Networks

Arrcus is a hyperscale networking software company founded in 2016 to enhance business efficiency through superior network connectivity. The company's flagship product is the Arrcus Connected Edge (ACE) platform, which offers core, edge, and multi-cloud routing and switching infrastructure. ACE provides best-in-class networking with a flexible consumption model and low total cost of ownership.
A key component of ACE is FlexMCN, a multi-cloud networking solution that creates a unified overlay fabric from edge to multi-cloud. In January 2024, Arrcus added Egress Cost Control (ECC) to FlexMCN, which can potentially reduce cloud connectivity costs by up to 40%. FlexMCN with ECC provides visibility into egress costs and dynamically routes traffic to destinations with the lowest costs across hybrid, colocation, and public cloud environments.
Arrcus' technology is designed to work with white-box hardware from multiple manufacturers, freeing customers from vendor lock-in. The company's solutions support leading enterprise, cloud, and communications providers with software-defined routing and switching. Arrcus claims to own more than 215 patents on its networking technology.
Key customers and partnerships
Arrcus serves enterprises in various industry verticals, including telecommunications, cloud providers, retail, finance, and software-as-a-service companies. The company has forged partnerships with industry-leading customers and partners such as SoftBank, Liberty Global, CoreSite, VMware, and Red Hat.
In February 2024, Arrcus announced a strategic collaboration with Red Hat to deliver innovative 5G, edge, and multi-cloud networking solutions for service providers. This partnership aims to enable service providers to monetize infrastructure with new revenue streams and drive operational efficiency while reducing costs and power consumption.
Arrcus has also partnered with Intel to deliver unified cloud connectivity for enterprises and communication service providers. This collaboration combines Arrcus' multi-cloud networking solution with Intel's expertise in high-performance computing to create seamless cloud computing environments for customers.

Using real-time data to create dynamic virtual representations of the real world

Digital Twin

Makersite is a developer of digital twin software for supply chain operations in manufacturing sectors. It uses AI and graph technology to map portfolio products, suppliers, and processes to construct digital twins for each product, thereby enabling users to gain control over its supply chain.&nbsp;&nbsp;The platform has over 50 analytical applications, including costing, compliance, and supply chain risk, and has access to over 140 external databases. The company operates a B2B2C business model, offering services to consultants, small businesses, and enterprises. The pricing for the platform starts from USD 13,000 (EUR 12,000) per year for small businesses and then increases in price for teams and enterprises.&nbsp;&nbsp;Key customers and partnershipsThe company has several integration partners, including Trinity, Wolters Kluwer Enablon, Accenture, AECOM, and GreenDelta to assist customers with the implementation of Makersite solutions. In May 2022, the company partnered with Beroe Inc to integrate Makersite’s database to Beroe’s solution to offer a multi-tier supply chain risk assessment. Also, in September 2022, the company announced Autodesk as its sustainability analytics partner. Further, in January 2024, the company partnered with WSP to combine Makersite’s technology with WSP’s expertise in EHS &amp; ESG consulting. Furthermore, the company’s key customers include Microsoft, Vestas, Cummins, Hitachi Solutions, and Procter &amp; Gamble.Funding and financialsThe company raised USD 18 million in October 2022 in a Series A funding round led by Hitachi Ventures. The new funds were allocated toward expanding its customer base.&nbsp;&nbsp;

Threat Prevention Toolchain

StrikeReady offers an AI-powered security operations and management platform designed to empower and augment cybersecurity teams. Founded in 2019, the company's flagship product is a cloud-based Cognitive Security Platform featuring CARA, an intelligent virtual security assistant. CARA leverages artificial intelligence, machine learning, and natural language processing to analyze data, automate processes, and provide guidance to security analysts across various teams including SOC, incident response, threat intelligence, and vulnerability management.
The platform integrates with organizations' existing security tools, unifying the entire tech stack to maximize utilization and ROI. It aims to address challenges like alert overload, the cybersecurity skills gap, and the evolving threat landscape by streamlining operations and enhancing analyst capabilities. StrikeReady's technology goes beyond traditional AI and large language models, utilizing a proprietary large action model (LAM) that can take actions across the technology stack based on user prompts. The platform includes capabilities such as threat intelligence, case management, risk-based vulnerability management, and security automation and response.
Key customers and partnerships
StrikeReady has expanded its customer base across security-centric industries including financial services, healthcare, legal, and retail. Some of its notable clients include Aflac, CNA Financial Corporation, Eventbrite, Goodwin, L.L. Bean, NOV, and Nutanix. The company has integrated its platform with over 400 third-party products across 15 technology categories, enhancing its threat intelligence engine and expanding integrations with cloud providers like Google, Microsoft, and AWS. This allows StrikeReady to enable end-to-end security in on-premises, cloud, or hybrid customer environments.

Redefining hospital care with the comfort of home

Hospital-at-Home

Huma Therapeutics is a global digital health technology company founded in 2011 and headquartered in London, England. The company develops software and platforms to support digital-first care delivery and research, aiming to help people live longer, fuller lives. Huma's modular platforms are used by over 3,000 hospitals and clinics across more than 70 countries, serving 1.8 million active patient users. The company's technology enables remote patient monitoring, virtual wards, and decentralized clinical trials. Huma's platform has been shown to almost double clinical capacity, reduce hospital readmissions by over a third, and improve participant retention and protocol adherence in clinical studies. In July 2024, Huma launched the Huma Cloud Platform, a no-code platform that allows developers to create disease-management tools using pre-built modules and device-connectivity capabilities. This platform is FDA Class II, EU MDR Class IIb, and UK MHRA Class IIb certified, enabling rapid development and deployment of digital health applications. Huma's technology incorporates artificial intelligence and is designed to be disease- and device-agnostic. The company has partnered with Google to develop AI models that enhance patient management capabilities.
Key customers and partnerships
Huma has established partnerships with several major pharmaceutical companies and healthcare organizations. In March 2022, Huma announced a partnership with AstraZeneca to scale innovation for digital health, including the development of Software as a Medical Device (SaMD) companion apps for several therapeutic areas. The company also works with the National Health Service (NHS) in the UK, as well as the governments of Germany and the United Arab Emirates. In May 2022, Huma entered into a 5-year deal with Tamer, the Middle East's leading healthcare distribution company, to bring its technology platform to Saudi Arabia, initially focusing on diabetes and cardiovascular disease management. In May 2024, Huma collaborated with Merck KGaA to launch a bladder cancer treatment companion app in the UK, developed with input from patient organizations and clinicians. The app provides personalized treatment and symptom management tools, educational resources, and medication reminders for bladder cancer patients.

Cyclic Materials provides recycling services that recover rare earth elements aiming to reduce the opening of new mines and accelerate the transition to electric mobility and cleaner energy. It operates landfill-bound products and recovering their critical metals that help businesses in supplying wind turbines, electric vehicles, and electronics segments by reducing CO2 emissions.

ArsenalBio is building a programmable cell therapy company to create highly effective and accessible immune cell therapies to impact outcomes for a much broader number of patients, initially those with cancer. Founded in 2019, ArsenalBio is focused on integrating technologies such as CRISPR-based genome engineering, scaled and high throughput target identification, synthetic biology, and machine learning to advance a new paradigm to discover and develop immune cell therapies. With its programmable and computationally driven approach, ArsenalBio aspires to evolve critical metrics of success for immune cell therapies, including enhanced and broader efficacy, increased patient safety, reduced provider costs and expanded market access.

Ema offers a Universal AI employee designed to automate complex workflows and improve productivity within organizations. Utilizing the Generative Workflow Engine, Ema integrates seamlessly with enterprise applications, allowing users to delegate repetitive tasks efficiently. The platform combines multiple AI models to ensure accuracy and security, making it a valuable asset for various business functions such as customer support, HR, and finance.

Lineaje solves critical Software Supply Chain security problems faced by every organization that builds, uses or sells software.

Arrcus offers hyper-scale networking software that provides software-powered network transformation for the interconnected world. The company's software improves human experiences by connecting people, machines, and data, and it provides simple-to-use software that spans the infrastructure, from routers to switches to servers, allowing businesses to unify manageability and control with the ease of a single network solution that works across the entire network infrastructure and simplifies operations. Arrcus was established in 2016 in San Jose, California by Devesh Garg.

Huma is a global health technology company that provides a modular platform to support digital 'hospitals at home' across different disease areas. Its platform combines predictive algorithms, digital biomarkers, and real-world data to advance proactive, predictive care and research. The company's technology integrates data from hospital databases, patient wearables, and mobile devices to provide real-time information to healthcare providers.

Samsara Eco is an enviro-tech company creating infinite recycling to end plastic pollution.

Trustwise is an AI safety startup on a mission to democratize AI that is safe, observable, and compliant.

WEKA is the AI-native data platform company that is setting the standard for AI infrastructure with the industry’s only cloud and hardware-agnostic software solution for performance-intensive applications. The WEKA® Data Platform delivers unprecedented performance at scale, transforming stagnant data silos into dynamic data pipelines that help enterprise AI, ML, and GPU workloads run faster and more efficiently and providing seamless data access on-premises, in the cloud, at the edge, and in hybrid and multicloud environments. WEKA helps hundreds of the world’s leading enterprises and preeminent research organizations overcome complex data challenges to reach discoveries, insights, and outcomes faster – including 11 of the Fortune 50.

StrikeReady empowers defenders of all levels to solve the technology exhaustion, skilled-talent shortage and limited collaboration problems. The StrikeReady platform consolidates key stand alone technologies, and integrates seamlessly into the tech stack, streamlining workflows, automation and collaboration. This operationally efficient platform delivers better ROI from your security investment, more effective and dynamic automation that works out-of-the-box, and a team that can finally lean forward into proactive security and risk management.

Archetype AI is a group of designers and technologists they are pioneering revolutionary artificial intelligence and interaction technologies for the real world.

WASE provides a decentralized sanitation system with the goal of accelerating the global adoption of circular waste treatment. The company was founded in 2017 and is headquartered in London.

Cure51 mission is to create a database of cancer survivors to leverage their exceptional biological features and find new drugs to cure Cancer.

Thea Energy is taking a faster approach to commercialize fusion energy. The company’s fusion systems will create a limitless source of zero emission energy for a sustainable future. Thea Energy is leveraging recent breakthroughs in stellarator physics and engineering developed at Princeton University and elsewhere. The company was founded in 2022 with the objective of building modular, utility-scale fusion power.

Captura is a Direct Ocean Capture company that develops a carbon capture system to catch scalable carbon from the atmosphere. It develops cost-competitive carbon dioxide capture and sequestration technology to extract it from ocean water to meet the rapidly growing demand in the credit market. Its system combines innovative technology with the natural carbon removal powers of the ocean to remove CO2 from the atmosphere at a large scale and low cost, providing a critical capability in the fight against climate change.

Proscia develops a digital pathology platform to assist routine pathology operations, enhance cancer diagnosis, and improve patient outcomes. Its platform utilizes computing technologies that unlock hidden data not visible to the human eye and turns that data into valuable insights to help physicians accelerate the development of life-saving advances.

Pow.bio provides intelligent fermentation services for industrial and synthetic biology, helping turn great ideas into profitable products. We combine continuous fermentation with advanced control methodology to quickly optimize your fermentation process and deliver high yields at low costs. Our scale runs from 1-100 liter capacity for bacteria, yeast, and filamentous fungi.

Ascend Elements manufactures advanced battery materials using valuable elements reclaimed from spent lithium-ion batteries. It uses hydroprocess recycling and direct recycling, which take old cathode material down to the atomic level to create new cathode materials. It also helps clients have the maximum return on assets to economically drive recycling and low-cost battery materials.

Strangeworks makes the power of quantum computing accessible to everyone all in one place. Learn more at http://quantumcomputing.com

BeZero Carbon the carbon ratings agency. Investing in carbon projects is essential to tackling climate change. Independent, risk-based, project level carbon ratings are essential to that investment. Our carbon ratings and risk tools equip world-leading organisations with the knowledge, tools and confidence to make better climate decisions. Our aim is to scale investment in environmental markets that deliver a sustainable future.

Makersite is a cloud-based product data management tool that helps companies manage product sustainability, cost, and compliance. Product life cycle management involves making design decisions based on multiple criteria including cost, compliance, sustainability, and risk. Unfortunately, the data and expertise required to make these decisions are siloed. This protracts the process of innovation and increases its complexity.  Today, the market solves this problem with vertical applications like PDM, ERP, CAD, EHS, SCM, etc. These mostly remain siloed due to the enormous costs of integration and keeping data synchronized. Therefore, analyses typically require exporting data to aggregation tools e.g. BI or excel before being used for analyses in specialist decision support applications. Results are typically delayed, some taking as much as 9 months, and therefore provide little support during the design process. Makersite provides results instantly and simultaneously across key product criteria. Makersite combines external and internal data sources to create a digital twin of a product in design. Artificial intelligence and its graph-based data model allow for ingesting, representing, and connecting heterogeneous data easily. Its native applications use algorithms to support analysis and decision-making based on multiple criteria simultaneously including should-costs, regulatory compliance, life cycle impacts (LCA), supply chain risk, etc. The API-first architecture allows for easy integrations into existing IT infrastructures thereby supporting systems and processes with richer, fresher, and more timely product data. This allows engineers to understand and improve their designs from the perspective of their regulatory compliance, environmental impact, supply risk, and cost of production, simultaneously. Companies can get results up to 40x faster than traditional methods while making their products better.

Taranis develops an agriculture intelligence platform that utilizes sophisticated computer vision, data science, and deep learning algorithms to effectively monitor fields. It offers a full-stack solution for high-precision aerial surveillance imagery to prevent crop yield loss due to insects, crop disease, weeds, and nutrient deficiencies.

Scipher Medicine develops a healthcare platform designed to determine which drug will work best for each patient. The company is committed to transforming the way providers prescribe drugs, as well as the way manufacturers, develop new drugs. They are building a molecular map of all protein interactions that identifies genomic signatures and links those to disease and predictive treatment outcomes. Using a simple blood sample to analyze RNA, Scipher Medicine can predict if a patient is likely to respond to a targeted therapy before therapy is prescribed. This insight allows patients to start the most effective therapy from day one. For its first commercial product, they have developed PrismRA®, a first-of-its-kind blood test that can predict which patients with rheumatoid arthritis are less likely to respond to TNFi therapies such as Humira® and Enbrel® so that such patients can go on alternative approved drugs.   Scipher Medicine is building the future of patient treatment. Most patients who are prescribed blockbuster therapies today don't respond to treatment, costing the healthcare industry billions in wasted drugs while patients continue to suffer. Scipher's platform identifies which drug will work based on the patient's fundamental disease biology, and not based on symptoms, disease classification, or medical bias. A routine blood test predicts which drug he/she will respond to, with our first product focusing on rheumatoid arthritis, ensuring that the most optimal treatment is prescribed from day one. The molecular data generated by our tests are then used to fuel novel target discovery to address a clear unmet medical need in patients who do not respond to any existing therapy.

Provectus Algae is a biotechnology company specializing in the optimization of microalgae species to produce high-value biobased chemicals, specialty ingredients, and biologics for use in a wide array of industries and applications. Provectus Algae enables groundbreaking capabilities with a well-balanced fusion of innovative proprietary technology and a thorough knowledge of the unique biological traits of microalgae. By leveraging advanced automation, machine learning, and synthetic biology approaches, Provectus Algae can rapidly develop, execute, and license biomanufacturing processes depending on the needs of our commercial partners. Microalgae biotechnology holds tremendous potential for countless industries and products, thanks to microalgae’s impressive biochemical diversity, sophisticated biosynthesis machinery, and rapid growth rates, among other functional attributes. Importantly, photosynthetic microalgae species can also turn CO2 into valuable and in-demand biomolecules, providing the life science community with a powerful mechanism for adopting more sustainable biomanufacturing processes and reducing carbon footprint. Provectus Algae has built an end-to-end biomanufacturing platform capable of taking microalgae-based products from discovery to large-scale production, actualizing the full potential of microalgae biotechnology. We have brought together the combined strengths of our talented multidisciplinary team to rapidly build scalable microalgae production systems and source high-value compounds for our partners in the food & beverage, cosmetic, therapeutic, and agricultural industries.

Rescale is a cloud simulation platform that enables research scientists and engineers to build, compute, analyze, and scale simulations. The high-performance computing cloud platform delivers intelligent computing for digital R&D and enables more than 300 customers from startups to Fortune 50 enterprises to accelerate design cycles and time to market. Rescale gives research scientists and engineers the ability to run their simulation and artificial intelligence workloads on the cloud provider of their choice, using specialized hardware architectures and software templates optimized for their use cases, without any set-up or maintenance. Investors such as Initialized Capital, Keen Venture Partners, SineWave Ventures, Data Collective, ITV Ventures, Jump Capital, and M12 (formerly Microsoft Ventures), as well as Mitsubishi UFJ Capital, Quiet Capital, Streamlined Ventures, Translink Capital, Two Roads Group, Y Combinator, Hitachi Ventures, Nautilus Venture Partners, NVIDIA, Republic Labs, and Samsung Catalyst Fund backs Rescale. In 2011, Joris Poort and Adam McKenzie headquartered the company in San Francisco, California.

inVia Robotics provides the next generation of robotics warehouse automation solutions for e-commerce distribution centers and supply chains. As the developer of the world's first ''Robotics-as-a-Service'' autonomous mobile robot picking and goods-to-person system, inVia is powering the future of warehouse productivity without disrupting the ecosystem of a business's operations.

ThinkIQ develops a supply chain management cloud-based software designed to combine existing disparate and siloed supply chain data with modeling technology to detect material movements. Its software integrates advanced cloud, big data management, and time series historian technology to provide context for the data and correlate events over time to enable end-to-end granular supply chain visibility, allowing manufacturers and enterprises to generate significant financial savings and improve engagement with customers. The company was founded in 2015 and is headquartered in Aliso Viejo, California.

SOPHiA GENETICS is a healthcare technology company dedicated to establishing the practice of data-driven medicine as the standard of care and for life sciences research. It is the creator of the SOPHiA DDM™ Platform, a cloud-based SaaS platform capable of analyzing data and generating insights from complex multimodal data sets and different diagnostic modalities. The SOPHiA DDM™ Platform and related solutions, products and services are currently used by more than 780 hospital, laboratory and biopharma institutions globally.

Hitachi Ventures invests in innovative companies that address society’s key technological challenges in areas like IT, industrial automation (robotics, sensor technology and IoT), cloud services (data management, cybersecurity), mobility (autonomous driving, mobility services, smart infrastructure and security services), energy, smart medicine (AI for digital imaging, smart diagnostics, remote care), smart city, smart infrastructure and more.  With our first fund of USD 150M, we invest in Series A/B/C rounds in globally leading startups. From our offices in Munich, Germany, and Boston, USA, we work tirelessly to develop close ties and effective collaboration with leading innovative technology hubs and like-minded co-investors. Hitachi intends to leverage its strong position in multiple global technology markets, its expertise and network to support and promote Hitachi Ventures portfolio companies.

Hitachi Ventures

Portfolio

About EDGE

Contact Us

Resources

Area of Focus

Technology Research Made Effortless